RT Journal Article
SR Electronic
A1 Kuznar, Wayne
T1 Sifalimumab Slows Disease Activity in SLE
JF MD Conference Express
YR 2014
FD SAGE Publications
VO 14
IS 51
SP 7
OP 8
DO 10.1177/155989771451003
UL http://mdc.sagepub.com/content/14/51/7.abstract
AB An investigational anti-interferon-a monoclonal antibody, sifalimumab, reduced global disease activity in patients with systemic lupus erythematosus (SLE). This article presents results from a phase 2b study of sifalimumab in patients with moderate to severe SLE.